1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 02 NOVEMBER 2015

Cancer Drug News 02 NOVEMBER 2015

  • November 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - World's First Oncolytic Viral Therapy Adds Contender To Melanoma Market
Industry Brief - Igenica/MedImmune Enter Oncology Research Collaboration
Industry Brief - Celgene's Vidaza Approved In Europe For Elderly Patients With AML
Industry Brief - Stemline's SL-401 Gains EU Orphan Designation For BPDCN
Industry Brief - Keytruda Superior To Chemotherapy In PD-L1-Expressing NSCLC
Industry Brief - Telesta/Ipsen Sign Ex-US Licensing Deal For MCNA In High-Risk NMIBC
Industry Brief - Keytruda Gains FDA Breakthrough Therapy Designation For Advanced CRC
Industry Brief - FDA Approves Yervoy As Adjuvant Treatment For Stage III Melanoma
Industry Brief - Lenvima Launched In Switzerland
Industry Brief - Kite To License AIS' TIP Technology To Advance CAR/TCR Product Candidates
Industry Brief - MacroGenics Regains Global Rights To Enoblituzumab
Industry Brief - ProBioGen and Bio Farma Enter Trastuzumab Agreement
Industry Brief - Orexo Settles Fentanyl Litigation With Actavis
Industry Trend Analysis - Metabolic And Oncology Areas To Support Growth Prospects

Table Of Contents

Cancer Drug News 02 NOVEMBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.